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Introduction: Induction methods for therapeutic cooling are under investigated. We compared the effectiveness
and safety of cold infusions (CI) and nasopharyngeal cooling (NPC) for cooling induction in stroke patients.
Methods: A prospective, open-label, randomised (1:1), single-centre pilot trial with partially blinded safety endpoint
assessment was conducted at the neurointensive care unit of Heidelberg University. Intubated stroke patients with
an indication for therapeutic cooling and an intracranial pressure (ICP)/temperature brain probe were randomly
assigned to CI (4°C, 2L at 4L/h) or NPC (60L/min for 1 h). Previous data suggested a maximum decrease of tympanic
temperature for CI (2.1L within 35 min) after 52 min. Therefore the study period was 1 hour (15 min subperiods I-IV). The
brain temperature course was the primary endpoint. Secondary measures included continuous monitoring of neurovital
parameters and extracerebral temperatures. Statistical analysis based on repeated-measures analysis of variance.
Results: Of 221 patients screened, 20 were randomized within 5 months. Infusion time of 2L CI was 33 ± 4 min in 10
patients and 10 patients received NPC for 60 min. During active treatment (first 30 min), brain temperature decreased
faster with CI than during NPC (I: −0.31 ± 0.2 versus −0.12 ± 0.1°C, P = 0.008; II: −1.0 ± 0.3 versus −0.49 ± 0.3°C,
P = 0.001). In the CI-group, after the infusion was finished, the intervention no longer decreased brain temperature,
which increased after 3.5 ± 3.3 min. Oesophageal temperature correlated best with brain temperature during CI and
NPC. Tympanic temperature reacted similarly to relative changes of brain temperature during CI, but absolute values
slightly differed. CI provoked three severe adverse events during subperiods II-IV (two systolic arterial pressure (SAP),
one shivering) compared with four in the NPC-group, all during subperiod I (three SAP, one ICP). Classified as
possibly intervention-related, two cases of ventilator failure occurred during NPC.
Conclusions: In intubated stroke patients, brain cooling is faster during CI than during NPC. Importantly,
contrary to previous expectations, brain cooling stopped soon after CI cessation. Oesophageal but neither
bladder nor rectal temperature is suited as surrogate for brain temperature during CI and NPC. Several severe
adverse events in CI and in NPC demand further studying of safety.
Trial registration: ClinicalTrials.gov NCT01573117. Registered 31 March 2012Introduction
Experimental data suggest that compared with late treat-
ment initiation, early commencement of cooling delivers
superior neuroprotection in cardiac arrest and stroke [1,2].
Several methods for induction of therapeutic cooling are
available [3], but these methods are underinvestigated with* Correspondence: christian.hametner@med.uni-heidelberg.de
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ters [4]. The present study focused on intravenous cold in-
fusions (CI) and the RhinoChill device for nasopharyngeal
cooling (NPC; BeneChill, Inc., San Diego, CA, USA).
CI represent the current clinical standard for hypothermia
induction in cardiac arrest [5-7] and are presently being
used for induction of hypothermia in two large trials
investigating the outcome of stroke [8,9]. However, no
evidence exists on the efficacy of CI with regard to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Inclusion/exclusion criteria
Inclusion criteria: Exclusion criteria:
○ Ischaemic or haemorrhagic
stroke
○ Severe cardiac insufficiency
(NYHA ≥ III)
○ ICP/temperature brain probe ○ Acute myocardial infarction or
pulmonary embolism
○ Indication for therapeutic
cooling independent of the
study
○ Threatened ventricular dysrhythmia
or cardiac dysrhythmia (heart rate
<50/min, QTc >450 ms, sick sinus
syndrome, AV block II-III°)
○ Sedation, intubation, and
mechanical ventilation
○ Chronic sinusitis or current or past
fracture or surgery of the paranasal
sinuses not allowing secure
application of nasopharyngeal
cooling
○ Age ≥18 years ○ Severe infection with bacteraemia
or sepsis ≤72 h
○ Written informed consent by
patient or legal representative
○ Fever >38.5°C
○ Severe renal or liver insufficiency
○ Known haematologic disease with
increased risk of thrombosis (e.g.,
cryoglobulinaemia, cold agglutinins
or sickle cell anaemia)
○ Known vasospastic vascular disorder
(e.g., Raynaud phenomenon or
thromboangiitis obliterans)
○ Body weight >120 kg
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tion [10]. Measuring tympanic temperature in stroke pa-
tients, previous data of CI (2.1 L within 35 minutes)
showed a maximum temperature decrease, in mean, of
1.6°C after 52 minutes [11]. Data on the safety of CI in
stroke patients are also urgently needed. The usefulness of
four observational studies (n = 3 to 36) [11-14] and one
small randomised controlled trial (n = 10) [15] is limited
by their intermittent rather than continuous circulatory
measurements when administering CI, and no data are
available on neuromonitoring. Furthermore, a cardiac ar-
rest trial recently found that early hypothermia induction
with CI improved neither the survival nor the neurological
status of the patients and was associated with an increased
rate of pulmonary oedema [16].
NPC is a new method to induce cooling. Both Castrén
and Busch with their respective colleagues demonstrated
the feasibility and safety of NPC in the prehospital
cardiac arrest setting [17,18], and Abou-Chebl et al.
provided data on brain cooling in brain-injured patients
(−1.4°C within one hour) [19]. We confirmed this cooling
rate in stroke patients (−1.2°C after 58 minutes), but
highlighted critical rises in blood pressure (BP) as a poten-
tially important adverse effect (AE), warranting further in-
vestigation [20].
The Rapid Induction of COOLing in Stroke Patients
trial (iCOOL1) is investigating, for the first time, the ef-
fect of CI on brain temperature and comparing CI and
NPC in their brain cooling efficacy and safety during
cooling induction. Secondary measures comprise a safety
evaluation, including continuous monitoring of neurovi-
tal parameters, and the analysis of temperature dynamics
at different extracerebral monitoring sites to find a valid
surrogate for brain temperature during cooling induc-
tion with either CI or NPC.
Materials and methods
Study design, approval
iCOOL1 is a prospective, interventional, open-label, two-
armed, randomised, single-centre pilot trial with partially
blinded safety endpoint assessment (see Randomisation
and blinding). Clinical Trial Registration Information [21]
unique identifier is NCT01573117. Institutional Review
Board approval was obtained from the ethics committee
of Heidelberg University (protocol no. S-301/2010). In-
formed consent was obtained from patients (whenever
competent) or their legal representatives before enrolment
in the study.
Setting and eligibility criteria
The study was conducted at the neurointensive care unit
(NICU) of the Department of Neurology at Heidelberg
University, a tertiary care hospital including a neurovas-
cular centre.Our NICU has 12 ventilator-equipped beds and more
than 200 severe stroke patients are treated per year. Be-
tween June and November 2011 all admitted patients were
screened and, if eligible, enrolled prospectively. The inclu-
sion and exclusion criteria are listed in Table 1.
In all patients, neurological intensive care physicians
had prescribed therapeutic cooling and placement of a
combined intracranial pressure (ICP)/temperature brain
probe independent of the study (Neurovent Temp or
Neurovent PTO, accuracy ± 0.1°C; Raumedic, Muenchberg,
Germany; inserted >3 cm below the cortical surface).
According to our standard operating procedure, thera-
peutic cooling targeting normothermia is indicated when
body core temperature rises above 37.2°C [22]. Thera-
peutic hypothermia as a compassionate measure for treat-
ment of cerebral oedema has been implemented at our
institution since 1998 [23], even though the treatment is
experimental. All patients were intubated and deeply
sedated and showed no response to painful stimuli, in-
cluding pinching of the nasal septum (RASS-5, Rich-
mond Agitation Sedation Scale). Our standard regimen
for sedation and analgesia included the combination of
either midazolam and sufentanil or propofol and remifen-
tanil. Pressure-controlled continuous mandatory ventila-
tion (pc-CMV) was applied (SERVO-s/-I; Maquet, Rastatt,
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gases (PaO2 80 to 110 mmHg, PaCO2 35 to 45 mmHg).
Interventions
Patients were randomised to CI (intervention A) or NPC
(intervention B).
Intervention A: Two litres of cold (4°C) isotonic saline so-
lution (0.9% NaCl) were infused intravenously via a cubital
vein catheter (18 gauge or larger) at a constant flow rate of
4 L/hour using a Power Infuser (ZOLL, Sunnyvale, CA,
USA). We chose the same volume and infusion rate as
employed in most cardiac arrest trials [5,16] and imple-
mented in previous and current stroke trials [9,11-15,24].
Intervention B: NPC has been described in detail by
others [17,18]. Briefly, NPC uses nasal catheters to spray
an inert coolant (perfluorohexane) at a high flow rate
into the nasal cavity. A lidocaine spray was applied be-
fore introduction of the nasal catheters. At treatment
initiation, the flow rate was gradually increased over a
period of 2 minutes until a rate of 60 L/minute was
reached. NPC was applied for one hour.
During both interventions (A, B) no other cooling
procedures were allowed.
Outcome
Because previous data suggested a maximum decrease of
tympanic temperature for CI (2.1 L within 35 minutes)
after 52 minutes, a study period of one-hour was chosen.
The primary endpoint was defined as the change in
brain temperature within one hour after treatment initi-
ation. For better assessment of dynamic temperature
changes, the one-hour study period was divided into
four predefined subperiods of 15 minutes duration (I to
IV). Secondary outcome measures were changes in body
temperature at different extracerebral monitoring sites
(tympanum, bladder, rectum and oesophagus), neurovital
parameters (arterial pressure, cerebral perfusion pressure
[CPP], heart rate [HR], ICP and oxygen saturation [SpO2])
and ventilation parameters during the one-hour study
period, and the assessment of various safety parameters,
such as shivering, blood and blood gas analyses, bleeding
complications, signs of acute heart failure, local irritations
in the nasopharynx and olfactory dysfunction up to six
months after cooling.
Critical values of neurovital parameters counted as se-
vere AE and were predefined according to our local guide-
lines as follows: systolic arterial pressure (SAP) >180
mmHg in ischaemic stroke and >160 mmHg in haemor-
rhagic stroke; ICP >20 mmHg; CPP <60 mmHg. Relevant
delta values were defined as changes in SAP > +20 mmHg
and ICP > +10 mmHg. Shivering was graded using the
bedside shivering assessment scale (BSAS, ranging from
0 = no shivering to 3 = severe shivering) [25]. BSAS
scores of 3 were classified as severe AE. Blood samplesfor blood gas analyses and blood analysis were drawn
before and two hours and twelve hours after the start
of cooling [see Additional file 1]. Cranial CT before
and after cooling induction and echocardiography were
part of the routine diagnostic assessment and the im-
ages obtained were evaluated by neuroradiologists and
cardiologists blinded for treatment allocation. Three
days after cooling induction, patients underwent oto-
rhinolaryngological (ORL) examination, including an-
terior and posterior rhinoscopy. ORL examination was
repeated ≥6 months after the intervention, adding a
standardised 16-item smell test with Sniffin’ Sticks.
The ORL physicians were also blinded for treatment
allocation.
Information about the medical equipment used can be
found in the supplementary methods section [Additional
file 2].Randomisation and blinding
An independent physician randomly allocated groups,
marked non-transparent envelopes sequentially, and sealed
them. S.P. and C.H. obtained the patient consents and
opened the envelopes in predefined order. Patients were
randomised at a 1:1 ratio to either of the two interventions:
(A) CI or (B) NPC. All neuroradiologists, cardiologists and
ORL physicians who examined the patients were blinded
to group allocation.Statistics
Statistical analysis was performed using MATLAB v7.12
(MathWorks, Natick, MA, USA) and SAS v9.2 (SAS, Cary,
NC, USA). The duration of baseline reading (15 minutes),
the division of the one-hour interventional period into four
subperiods (I to IV, 15 minutes each) and statistical ana-
lyses were predefined in the study protocol. Repeated-
measurements analysis of variance (ANOVA) with the
between-subject effect GROUP (CI versus NPC) and the
within-subject effect TIME (five measurements: baseline,
interventional periods I to IV) was used for the main statis-
tical analysis (correction according to Greenhouse and
Geisser). Further information is given in the supplementary
statistics section [see Additional file 2].Results
The study flow chart is shown in Figure 1. A total of 20
patients were enrolled in the study. Ten patients (seven
ischaemic, three haemorrhagic stroke) received 2 L of
CI in 33 ± 4 minutes and ten patients (four ischaemic,
six haemorrhagic stroke) were treated with NPC for
60 minutes.
Baseline characteristics and outcome data are shown
in Table 2.
Figure 1 Study flow chart.
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Brain temperature was similar in the two study groups
at baseline (CI 37.4 ± 0.4°C versus NPC 37.5 ± 1.1°C,
n.s.), but differed significantly during the intervention
(see Figure 2A): during the first 30 minutes of active
treatment with CI (subperiods I and II) brain tempe-
rature decreased faster than during NPC (I: −0.31 ±
0.2 versus −0.12 ± 0.1°C, P = 0.008; II: −1.0 ± 0.3 ver-
sus −0.49 ± 0.3°C, P = 0.001, after 30 minutes: −1.31 ± 0.4
versus −0.68 ± 0.3°C, P < 0.001). In the CI group, after the
infusion was discontinued, the intervention did not have a
further decreasing effect on brain temperature, but brain
temperature increased again after 3.5 ± 3.3 minutes. In
the NPC group, after an initial increase, the brain cooling
rate slightly decreased again during the course of active
treatment (I: −0.12 ± 0.1°C, II: −0.37 ± 0.1°C, III: −0.34 ±
0.1°C, IV: −0.27 ± 0.1°C; after 60 minutes: −1.23 ± 0.4°C).
All brain probes were inserted >3 cm below the cortical
surface. In the NPC group the distance between the probe
tip and the nasopharynx was 6.6 ± 1.7 cm. Only age dif-
fered significantly between the two groups (see Table 2)and body surface area (BSA) correlated with brain cooling
during NPC (r = 0.6, P = 0.049). Considering that, we
additionally performed analysis of covariance (ANCOVA)
with age and BSA as covariates; this analysis yielded com-
parable results. All other influencing variables (including
stroke type) listed in the supplementary statistics section




Data for surrogate temperature sites were available as
follows: tympanum (20/20), bladder (20/20), rectum
(CI 6/10, NPC 5/10), and oesophagus (CI 6/10, NPC 6/10).
At baseline, body temperature at all sites was similar
to brain temperature, with the exception of tympanic
temperature, which was slightly lower (37.5 ± 0.7 versus
37.1 ± 0.7°C, P < 0.001). During both interventions
oesophageal temperature correlated best with brain
temperature (n.s. for difference; see Figure 2B), whereas
decreases in bladder (P < 0.001) and rectal temperature






Patients; number 10 10
Female; number (%) 4 (40%) 5 (50%) n.s.a
Age, years; mean ± STD 65.4 ± 7.4 55.7 ± 11.5 0.038b
Weight, kg 83.5 ± 17.7 80.3 ± 12.7 n.s.b
Height, cm 173.1 ± 10.1 172 ± 10 n.s.b
Body mass index, kg/m2 27.9 ± 5.9 27.3 ± 2.4 n.s.b
Body surface aread, m2 2 ± 0.2 2 ± 0.2 n.s.b
Time from symptom onset
to treatment, hours
69.4 ± 25.2 67.1 ± 31.9 n.s.b
Stroke type; number (%) n.s.a
Ischaemic 7 (70%) 4 (40%)
ICH 2 (20%) 5 (50%)





0 7 (70%) 7 (70%)
1 2 (20%) 2 (20%)








4.5 (3.75-6) 4.5 (3–6) n.s.c
Risk factors; number (%)
Diabetes mellitus 0 (0%) 3 (30%) n.s.a
Arterial hypertension 8 (80%) 8 (80%) n.s.a
Hypercholesterolaemia 0 (0%) 1 (10%) n.s.a
Atrial fibrillation 2 (20%) 0 (0%) n.s.a
aFisher's exact test; bStudent’s t-test; cMann–Whitney U test.; dMosteller
formula. ICH, intracerebral haemorrhage; IQR, interquartile range; mRS,
modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; n.s.
non-significant; SAH, subarachnoid haemorrhage; STD, standard deviation.
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groups. Tympanic temperature correlated well with brain
temperature changes in patients receiving CI (n.s. for dif-
ference), but overestimated brain cooling in NPC-treated
patients (P = 0.005).
Neurovital parameters
Mean continuous curves of SAP, CPP, ICP and HR for
each intervention are given in Figure 3. In the CI group,
SAP, mean arterial pressure (MAP) and CPP were sig-
nificantly higher than baseline in all subperiods (I to IV)
and ICP was significantly increased during subperiods I
to III (P <0.05 for all). During NPC, only SAP and MAP
were significantly higher than baseline, and only in sub-
period I. In both groups, the level of sedation (RASS −5)remained unchanged during the one-hour study period,
and the changes of neurovital parameters did not correl-
ate with the underlying stroke type and the sedation
regimen.
Direct comparison of CI and NPC showed significantly
higher values in the CI group in subperiod II for SAP,
MAP, CPP and ICP (P <0.05). MAP and ICP were still
significantly higher in subperiod III (P <0.05). HR and
SpO2 saturation exhibited no significant differences be-
tween CI and NPC throughout the observation period.
CI provoked eleven intervention-related AEs of neuro-
vital parameters during subperiods II to IV, of which
three were classified as severe (two SAP, one shivering).
In contrast, all eight NPC-associated AEs were confined
to subperiod I. Four were classified as severe (three SAP,
one ICP). Severe AEs were treated according to the local
standard guidelines for management of BP, ICP and shiv-
ering. Intervention-related complications of individual
patients are listed in Table 3.
Respiratory parameters
Inspiratory tidal volume decreased during both interven-
tions, although ventilator settings were kept stable. Changes
were significant compared with baseline during subperiods
II to IV in the CI group and during subperiods III and IV
in the NPC group (P <0.05; see Figure 3C). In subperiods II
and III, inspiratory tidal volume decreased to a greater ex-
tent in the CI than in the NPC group (P <0.05).
Ventilator malfunction
Two cases of ventilator failure (SERVO-I) occurred during
NPC – 56 minutes and 24 minutes after treatment start.
In both cases, a change of the expiration cassette resolved
the issue. Ventilation was bypassed with an Oxylog3000
(Draeger, Luebeck, Germany) for sixteen minutes and six
minutes, respectively. The lowest SpO2 was 95% and 98%.
We classified both events as possible intervention-related
unanticipated serious adverse device effects (USADE).
Chart and laboratory assessment
CI significantly affected volume balance compared with
baseline and with the NPC group (CI 1,989 ± 190 ml
versus NPC 0 ± 188 ml, P <0.001). No differences in la-
boratory values (including arterial blood gases) between
the two treatment groups were found at any time. The
supplementary table presents the detailed laboratory
values [see Additional file 1].
Imaging
Safety evaluation of brain imaging revealed no new
bleeding events. In one patient the CT scan after NPC
showed a retention of fluid perfluorohexane (PFH; 560
Hounsfield units) in the left sphenoid sinus [20]. This














CI 4°C, 2L at 4L/h
NPC 60L/min































Figure 2 Brain and body temperatures. A) Mean brain temperature curves for CI (n = 10) versus NPC (n = 10) and corresponding 95%
confidence intervals (grey shading). B, C) Mean curves of all body temperature measurements in comparison with brain temperature during
treatment with CI (B) and NPC (C). Sampling rate for all data acquisition was 1/minute.
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CT examination two days later.
Otorhinolaryngological evaluation
ORL evaluation on day 3 was available for 17 patients
(CI 8/10, NPC 9/10). Overall, we observed four mild
AEs without the necessity of further treatment, two in
each interventional group. One patient in the CI group
experienced minor bleeding at the larynx, which most
likely occurred after tracheotomy was performed. In an-
other patient of the CI group, ichor but no mucosal defect
was found. One patient in the NPC group developed an


































Figure 3 Neurovital and respiratory parameters. A, B) Mean curves of
systolic arterial pressure; CPP, cerebral perfusion pressure; ICP, intracranial p
(n = 9) versus NPC (n = 9) and corresponding 95% confidence intervals (gr
interventional group. Sampling rate for all data acquisition was 1/minute.swollen nasal conchae. These two AEs were classified as
possibly intervention-related.
ORL evaluation at follow-up (>6 months) was available
in 10 patients (of the remainder, six had died, while four
declined examination). Rhinoscopic findings (CI five,
NPC five) and the 16-item smell test with Sniffin’ Sticks
(CI three, NPC five) were normal in all tested patients.
Discussion
Induction methods for therapeutic cooling are under-
investigated [4]. For the first time, the iCOOL1 trial
provides data on the effects of CI on brain temperature
and neurovital parameters, demonstrates that oesophageal30 45 60
eters: NPC
(min)














neurovital parameters during CI (A; n = 10), and NPC (B; n = 10). SAP,
ressure; HR, heart rate. C) Mean inspiratory tidal volume curves for CI
ey shading); respiratory data were not available for one patient in each
Table 3 Intervention-related AE
ID Intervention Stroke type Intervention-related AE Subperiod Treatment
2 CI Ischaemic No - -
3 CI Ischaemic BSAS 3 II Yes
4 CI Ischaemic ΔSAP +42 mmHg, SAP 186 mmHg III Noa
6 CI ICH ΔSAP +33 mmHg III No
9 CI ICH ΔSAP +43 mmHg III No
13 CI Ischaemic ΔSAP +39 mmHg, ICP 27 mmHg II Yes
15 CI Ischaemic No - -
16 CI Ischaemic ΔSAP +43 mmHg III No
17 CI Ischaemic ΔSAP +28 mmHg III No
19 CI SAH ΔSAP +18 mmHg, SAP 165 mmHg IV Yes
1 NPC Ischaemic ΔSAP +35 mmHg I No
5 NPC ICH No - -
7 NPC ICH BSAS 3 I Yes
8 NPC SAH ΔSAP +14 mmHg, SAP 160 mmHg I Yes
10 NPC Ischaemic ΔSAP +28 mmHg, SAP 187 mmHg I Yes
11 NPC ICH ΔSAP +40 mmHg I No
12 NPC Ischaemic ΔSAP +51 mmHg, ICP 27 mmHg I Yes
14 NPC ICH No - -
18 NPC ICH No - -
20 NPC Ischaemic ΔSAP +25 mmHg I No
aSAP rose to 186 mmHg, but resolved spontaneously before treatment was initiated. Intervention-related AE of neurovital parameters for each patient, with the
time of occurrence (subperiods I to IV), and whether or not the AE was treated. Treatment was indicated if SAP or ICP was higher than the predefined critical value
(SAP ischaemic stroke ≥180 mmHg, haemorrhagic stroke ≥160 mmHg; ICP ≥20 mmHg), or the BSAS score was ≥1. ΔSAP indicates maximum delta SAP compared
to baseline. BSAS, Bedside Shivering Assessment Scale; ICH, intracerebral haemorrhage; ICP, intracranial pressure; SAH, subarachnoid haemorrhage; SAP, systolic
arterial pressure.
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temperature during CI and NPC, and compares the effect-
iveness and safety of CI and NPC for induction of cooling
in stroke patients.
Brain cooling is faster during CI than during NPC
Subperiods I and II, the two subperiods during which
both groups were actively treated, revealed faster brain
cooling during CI (−1.31°C after 30 minutes) than dur-
ing NPC (−0.68°C after 30 minutes). In the CI group,
brain temperature reduction stopped only 3.5 minutes
after cessation of CI, and brain temperature increased
again (see Figure 2A). This is of great importance as it
implies that additional methods for maintenance cooling
should be commenced by the end of CI infusion in order
to avoid fluctuations of brain temperature. Repetition of
CI or infusion of higher volumes for bridging until
maintenance cooling are most likely not an adequate so-
lution owing to the high risk of harmful fluid overload
[16]. On the other hand, it seems possible to stretch the
duration of CI by decreasing the infusion rate. However,
this would probably result in a loss of cooling efficiency.
This is even more important, as the fast brain cooling
with CI in our trial was obtained with a well-controlledCI temperature of 4°C, which cannot be guaranteed
under all circumstances [26,27].
NPC yielded a continuous decrease throughout the 60
minutes of active treatment and reached −1.23°C at the
end of subperiod IV. This finding is consistent with
brain-cooling rates in patients who suffered traumatic
brain injury or stroke, as previously described by Abou-
Chebl et al. and our group [19,20]. In our observational
period of one hour we captured the post-treatment
period for the CI group, because an immediate increase
of brain temperature after CI cessation occurred. How-
ever, since this was rather unexpected, this was not stud-
ied in the NPC group. As suggested by Abou-Chebl and
colleagues we recorded the site of the brain temperature
measurement (probe tip), as this may influence cooling
rates during NPC [19]. The one-hour cooling rate (−1.2
versus -1.23°C) and the distance from the probe to the
nasopharynx (6.6 versus 6.4 cm) were comparable in the
two studies [20].
Yu and colleagues directly compared CI and NPC in a
porcine model of prolonged cardiac arrest and reported
that jugular vein temperature (measured as a surrogate
for brain temperature) decreased faster in pigs treated
with NPC [28]. This contrasts with our observation of
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proximity of the nasopharynx to a smaller brain and the
existence of the rete mirabile in pigs relative to humans
as well as the preserved cardiac circulation in stroke pa-
tients may explain these different findings. Considerations
drawn from porcine cardiac arrest experiments measuring
brain temperature, that NPC primarily cools the brain
[29,30] are not supported by our results in stroke patients;
in our study, oesophageal body core temperature de-
creased to the same degree as brain temperature.
Bladder temperature is unsuitable as a surrogate for
brain temperature during induction of cooling with CI
or NPC
Very limited reports have been published on surrogate
monitoring sites for brain temperature during rapid
temperature changes [31,32]. Until now, data compar-
ing brain temperature with temperatures in other parts
of the body during CI have been completely lacking.
In this study, temperature changes in bladder and rec-
tum, the most commonly used standard monitoring sites
for body core temperature in the ICU, failed to promptly
replicate brain temperature changes in both study groups
(Figure 2B,C). This is in accordance with the results of
Stone and colleagues, who investigated body temperatures
in patients undergoing deep hypothermic circulatory
arrest [32]. These authors also classified bladder and
rectal temperature measurements as unsuitable for de-
tecting rapid changes in brain temperature. Decreases
in oesophageal temperature, on the other hand, were
found to be accurate [32]. For the first time we can
now confirm these findings for CI and NPC.
Our findings are of great importance: All but one [33]
of the previously published large cardiac arrest/cooling
induction trials that used CI [5,16,26] or NPC [17,18]
monitored the slow-reacting bladder or rectal tempera-
tures, or did not distinguish between core temperatures
in different parts of the body but rather reported a com-
posite core temperature. Furthermore, none of these
studies monitored body temperature at the same site
during cooling induction and maintenance cooling. It is,
therefore, very unlikely that the fast increase of brain
temperature after CI cessation would have been detected
in those trials [34].
Intervention-related AE of neurovital parameters in
NPC-treated patients appear instantly, whereas onset is
delayed in patients receiving CI
Our findings confirm our previous observation [20]
that NPC may provoke immediate BP peaks even in
deeply sedated patients and independent of stroke type
(see Table 3). In our study, additional bolus medication
reliably resolved these BP peaks. The BP increase we
observed during CI seems to be directly linked to theadministered volume of fluid and also did not correlate
with the underlying stroke type. Tollofsrud et al. and
Polderman et al. also found transient BP increases
after CI in healthy volunteers and brain-injured patients
[13,35]. In contrast, Kollmar and colleagues reported no
BP increases in ten awake ischaemic stroke patients; how-
ever, they took measurements at 30-minute intervals,
which limits comparability [11].
Importantly, even though both induction methods in-
duced significant BP increases, brain imaging analysis
showed no intracranial bleeding complications, also in
those patients with haemorrhagic stroke. Nevertheless,
our observation of blood pressure increases in both groups
raises serious safety concerns especially when treating
hyperacute haemorrhagic stroke.
In contrast to NPC, CI induced a more or less pronounced
ICP increase in all patients, which, for the most part, can
also be ascribed to the intravascular volume increase with a
consecutive shift of intracranial compartments.
Furthermore, inspiratory tidal volume decreased to a
noteworthy extent. Since patients remained deeply se-
dated (RASS −5) and ventilator settings of pc-CMV were
not changed during the one-hour study period, an in-
crease in respiratory resistance due to volume expansion
[36] and cooling [37] may explain this finding.
We registered two cases of ventilator failure during
NPC. Both malfunctions were unanticipated and serious
(USADE) and are possibly intervention-related. In both
cases, a change of the expiration cassette resolved the issue.
In summary, our findings of increased BP and ICP as well
as other intervention-related and possibly intervention-
related AEs raise concern regarding the safety of CI (4°C,
2 L at 4 L/hour) and NPC in stroke patients. Further
study of safety is imperative before broader use.
Limitations
Our study has some limitations. Group sizes in this ran-
domised trial were rather small. However, a clearly de-
fined endpoint using repeated-measurements ANOVA
with a size of 10 in each group provided significant and
robust results. The lack of a control group without cool-
ing was inevitable, as inclusion was coupled to the
study-independent indication for therapeutic cooling. We
enrolled patients with different stroke entities (ischaemic
stroke, ICH and SAH), but neither during CI nor during
NPC brain cooling correlated with the underlying stroke
type. Furthermore, both the frequency and the severity of
adverse events were similar for the different stroke types
and interventions (see Table 3). The requirement for brain
temperature measurement inevitably leads to selection
bias, as nearly all patients with an ICP/temperature brain
probe are severely affected and all were intubated and se-
dated. Therefore, the findings of this study cannot be gen-
eralised to the very large majority of patients who are only
Poli et al. Critical Care 2014, 18:582 Page 9 of 10
http://ccforum.com/content/18/6/582mildly affected by stroke or who are treated in a prehospi-
tal setting. Fewer than 10% of patients with ischaemic
stroke need intubation, a prerequisite for NPC [38]. As
this trial was performed in one centre only, external valid-
ation of the results is necessary.
Conclusions
In intubated stroke patients brain cooling is faster during ac-
tive treatment with CI (4°C, 2 L at 4 L/hour) than during
NPC. Importantly, contrary to previous expectations, brain
cooling stopped soon after CI cessation. Our finding implies
that additional methods for maintenance cooling should be
commenced by the end of CI infusion in order to avoid fluc-
tuations of brain temperature. NPC may be an alternative in
intubated stroke patients when infusion of high volumes is
contraindicated. Oesophageal, but neither bladder nor rectal
temperature, is suited as surrogate for brain temperature
during CI and NPC. Tympanic temperature seems feasible,
too, during CI, when a certain offset in absolute values is
kept in mind. Several severe adverse events in CI and in
NPC demand further studying of safety.
Key messages
 First study showing the effect of CI on brain
temperature
 Brain cooling is faster during CI (4°C, 2 L at 4 L/hour)
than during NPC.
 Brain temperature increases again soon after
discontinuation of CI.
 Intervention-related AEs raise concern regarding the
safety of CI (4°C, 2 L at 4 L/hour) and NPC in
stroke patients.
 Oesophageal temperature is best suited as surrogate
for brain temperature during both CI and NPC.
Additional files
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